Recently, the United States has witnessed an intense legal and commercial confrontation between major pharmaceutical ...

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the future.

AON, a health insurance consultant, and Murphy Administration officials announced on Wednesday that premiums in the State ...

Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Economists around the world are expecting muted U.S. economic growth in coming quarters, and some indicators suggest a mild recession is a possibility. It may become difficult for investors to ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

The U.S. is having its worst year for measles spread in more than three decades, with a total of 1,288 cases nationally and ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Ireland has long been a global pharmaceutical powerhouse, hosting more than 90 pharmaceutical companies and employing around ...

S&P 500, Microsoft Corporation, JPMorgan Chase & Co, Eli Lilly and Company. Read 's Market Analysis on Investing.com ...